Lung Cancer Overview

Lung cancer represents one of the most consequential malignancies globally, accounting for substantial morbidity and remaining the leading cause of cancer-related mortality in most populations. Approximately 2 million new cases occur annually worldwide, with 1.8 million deaths attributed to the disease. The substantial gap between incidence and mortality reflects the often-late stage at diagnosis combined with the inherent difficulty of treating advanced disease. Despite these challenges, the past two decades have witnessed transformative advances in lung cancer care including molecular characterization that identifies subgroups responsive to targeted therapies, immunotherapy approaches that produce durable responses in some patients, refined surgical techniques, advanced radiation technologies, and screening programs that detect cancers at earlier stages.

The biology of lung cancer reflects the diversity of cells in the lung tissue and the various ways those cells can transform into cancer. The disease is broadly divided into two major categories with substantially different characteristics: non-small cell lung cancer (NSCLC) accounting for approximately 85 percent of cases and small cell lung cancer (SCLC) accounting for approximately 15 percent. Within these categories, multiple subtypes exist with distinct molecular features, growth patterns, and treatment implications.

Smoking accounts for approximately 80 to 90 percent of lung cancer cases. The risk increases with both intensity and duration of smoking. Smoking cessation reduces risk substantially over time, though some elevated risk persists for years after cessation.

For more on early signs, see Understanding Different Types of Cancer.

⸻

What Lung Cancer Is

Lung cancer arises from abnormal, uncontrolled growth of cells in the lung tissue. Most cancers originate from bronchial epithelial cells lining the airways, alveolar cells lining the air sacs, and various other cell types within the lung.

Lung cancer is broadly divided into two major categories: non-small cell lung cancer (NSCLC), which accounts for approximately 85 percent of cases, and small cell lung cancer (SCLC), which accounts for approximately 15 percent. The categories have substantially different characteristics, treatment approaches, and prognoses.

NSCLC Subtypes

NSCLC includes several subtypes. Adenocarcinoma is the most common subtype, accounting for approximately 40 percent of all lung cancers and more common in non-smokers and women. Squamous cell carcinoma accounts for approximately 25 to 30 percent of lung cancers and is more strongly associated with smoking. Large cell carcinoma accounts for approximately 10 percent of NSCLC, along with various other less common subtypes.

SCLC Characteristics

SCLC is characterized by aggressive growth and rapid progression, strong association with smoking, tendency for early metastasis, initial responsiveness to chemotherapy and radiation, and substantial recurrence risk despite initial response.

Pleural mesothelioma, while often grouped with lung cancers, originates from the pleural lining rather than lung tissue itself and has a strong association with asbestos exposure.

For more on staging, see Cancer Staging Explained in Detail: TNM System, Clinical Significance, and Treatment Implications.

⸻

Risk Factors

Various factors contribute to lung cancer risk.

Smoking

Smoking is the predominant risk factor for lung cancer, accounting for approximately 80 to 90 percent of cases. Risk increases with both intensity (cigarettes per day) and duration of smoking. Pack-years (number of packs per day multiplied by years smoked) measures cumulative exposure. Smoking cessation reduces risk substantially, though some elevated risk persists for years.

Environmental and Occupational Exposures

Secondhand smoke increases lung cancer risk in non-smokers — the risk is lower than active smoking but substantial. Radon is a naturally occurring radioactive gas that can accumulate in buildings and is the second leading cause of lung cancer in many populations; home testing identifies elevated radon levels that warrant remediation. Various occupational exposures also increase risk: asbestos, heavy metals (arsenic, chromium, nickel), chemical exposures (vinyl chloride, formaldehyde), and diesel exhaust. Environmental air pollution contributes additional risk, with particulate matter associated with elevated incidence.

Other Risk Factors

Family history of lung cancer increases individual risk, reflecting genetic predisposition and shared environmental exposures. Personal history of lung diseases including COPD and pulmonary fibrosis may affect lung cancer risk. HIV infection has been associated with increased lung cancer risk. Various other factors including specific genetic conditions and previous radiation therapy also contribute.

For more on early signs, see Early Signs and Symptoms of Cancer: What to Watch For and When to Seek Medical Evaluation.

⸻

Symptoms

Lung cancer symptoms vary and can be subtle, particularly in early stages.

Common Symptoms

Common symptoms include persistent cough that doesn't go away or worsens, coughing up blood (hemoptysis) even in small amounts, chest pain that may worsen with deep breathing or coughing, hoarseness, shortness of breath, wheezing, repeated lung infections, unexplained weight loss, and persistent fatigue. Many lung cancers are advanced at presentation because symptoms often develop late. Many early lung cancers are asymptomatic, with detection requiring screening or incidental imaging findings.

Specific Patterns and Paraneoplastic Syndromes

Various specific patterns can occur: apical lung cancers (Pancoast tumors) can produce shoulder and arm pain; brain metastases can produce neurological symptoms; bone metastases can produce bone pain; liver metastases can produce abdominal symptoms. Paraneoplastic syndromes occur when cancer produces symptoms through hormonal or immune effects rather than direct tumor effects, including hypercalcemia, SIADH, and Cushing syndrome.

For more on diagnosis, see How Cancer Is Diagnosed: From Initial Symptoms to Biopsy and Molecular Testing.

⸻

Screening

Screening for lung cancer in high-risk individuals supports earlier detection. Low-dose CT screening has demonstrated mortality reduction in randomized trials by identifying cancers at earlier stages when treatment is more effective.

Current recommendations generally include screening for adults age 50 to 80 years with a 20 pack-year or greater smoking history who are currently smoking or quit within the past 15 years. Various organizations have somewhat different specific criteria. Screening involves annual low-dose CT scans, evaluation of identified findings, and follow-up imaging or biopsy as appropriate.

Screening has limitations including false positives requiring follow-up, some false negatives, radiation exposure (low but cumulative), and anxiety from screening findings. The benefits exceed the risks for appropriately selected high-risk patients. Smoking cessation remains the most important intervention regardless of screening status.

For more on related considerations, see Most Commonly Misdiagnosed Conditions.

⸻

Diagnosis

The diagnostic process for lung cancer typically involves multiple elements.

Imaging

Imaging often begins with chest X-ray when symptoms warrant initial evaluation, CT of the chest for further characterization, PET-CT for staging when cancer is suspected or confirmed, and brain MRI for staging in many situations.

Biopsy and Pathology

Tissue biopsy provides definitive diagnosis. Various biopsy approaches include bronchoscopy with biopsy for accessible tumors, CT-guided percutaneous needle biopsy for peripheral tumors, endobronchial ultrasound (EBUS) for mediastinal lymph node sampling, and surgical biopsy when needed. Pathologic evaluation provides specific cancer type and subtype, molecular features, grade, and other information.

Molecular Testing

Molecular testing increasingly guides treatment for NSCLC, evaluating EGFR mutations, ALK rearrangements, ROS1 rearrangements, BRAF mutations, KRAS mutations, MET alterations, RET rearrangements, NTRK rearrangements, PD-L1 expression, and tumor mutational burden. These markers identify subgroups responsive to targeted therapies.

Staging workup typically includes PET-CT, brain imaging (MRI preferred), mediastinal evaluation (often EBUS), and bone scan in some situations.

For more on diagnostic workup, see How Cancer Is Diagnosed: From Initial Symptoms to Biopsy and Molecular Testing.

⸻

Staging

Staging determines extent of disease and guides treatment. The TNM system stages lung cancer based on T (primary tumor characteristics), N (regional lymph node involvement), and M (distant metastasis).

NSCLC Stages

NSCLC stages range from Stage I (localized cancer without lymph node involvement) through Stage II (larger tumors or limited lymph node involvement), Stage III (more extensive lymph node involvement, subdivided into IIIA, IIIB, and IIIC), and Stage IV (distant metastasis).

SCLC Staging

SCLC is often classified as limited stage (disease confined to one side of the chest, able to be encompassed within a tolerable radiation field) or extensive stage (disease beyond limited stage criteria). The TNM system can also be applied to SCLC.

Survival by Stage

5-year survival for Stage I NSCLC is approximately 60 to 75 percent. Stage II is approximately 35 to 55 percent. Stage III is approximately 15 to 35 percent depending on substage. Stage IV has been historically low (under 10 percent) but is improving with modern therapies, particularly for patients with targetable molecular features. Limited stage SCLC is approximately 15 to 30 percent, and extensive stage SCLC has been historically very low but is improving.

For more on staging, see Cancer Staging Explained in Detail: TNM System, Clinical Significance, and Treatment Implications.

⸻

Treatment of NSCLC

Treatment of NSCLC varies by stage and various other factors.

Early-Stage NSCLC

Stage I NSCLC treatment typically involves surgical resection (lobectomy typically) for operable patients, stereotactic body radiation therapy (SBRT) for selected patients who cannot have surgery, and sometimes adjuvant therapy based on specific features. Many Stage I patients are cured. Stage II NSCLC treatment typically involves surgical resection and adjuvant chemotherapy in many cases.

Stage III NSCLC

Stage III NSCLC treatment is more complex, involving various combinations of chemotherapy, radiation therapy, and sometimes surgery. The specific approach depends on substage and other factors. Immunotherapy may be added in some situations.

Stage IV NSCLC

Stage IV NSCLC treatment depends substantially on molecular features. Patients with targetable molecular alterations (EGFR, ALK, ROS1, BRAF, KRAS G12C, and various others) typically receive corresponding targeted therapies. Patients with high PD-L1 expression often receive immunotherapy. Patients with neither targetable alterations nor high PD-L1 typically receive combination chemotherapy with immunotherapy. Modern outcomes for Stage IV NSCLC have improved substantially due to targeted therapies and immunotherapy, with some patients achieving durable responses or substantial long-term survival.

For more on consultation, see When Should You See an Oncologist? Early Warning Signs Explained.

⸻

Treatment of SCLC

SCLC treatment differs substantially from NSCLC.

Limited stage SCLC treatment typically involves combination chemotherapy, concurrent or sequential thoracic radiation therapy, and prophylactic cranial irradiation (PCI) in selected patients to reduce brain metastasis risk.

Extensive stage SCLC treatment typically involves combination chemotherapy and immunotherapy in addition to chemotherapy, sometimes with radiation therapy for specific situations. SCLC recurrence is unfortunately common, with various second-line treatments available at variable response rates. Newer approaches including immunotherapy combinations are improving outcomes.

⸻

Side Effects of Treatment

Lung cancer treatments produce various side effects. Surgery can produce pain, reduced lung function, and various surgical complications. Chemotherapy can produce fatigue, nausea and vomiting, hair loss, and lowered blood counts. Radiation therapy can produce skin reactions, esophagitis, and lung tissue effects. Targeted therapies have specific side effect profiles depending on the agent. Immunotherapy can produce immune-related adverse events affecting various organs.

For more on side effects generally, see Side Effects of Cancer Treatments.

⸻

Smoking Cessation and Lung Cancer

Smoking cessation matters at multiple stages of lung cancer care. Cessation prevents most lung cancers, with risk decreasing substantially over time. After diagnosis, smoking cessation improves treatment outcomes, reduces complications, and improves quality of life — it is never too late to stop smoking. Smoking cessation by family members of lung cancer patients also reduces secondhand smoke exposure. Various resources support smoking cessation including counseling and pharmacological aids.

For more on related topics, see Most Commonly Misdiagnosed Conditions.

⸻

Common Misconceptions

Several misconceptions about lung cancer deserve attention.

• Only smokers get lung cancer — While smoking is the major risk factor, non-smokers can develop lung cancer through various other risk factors.
• Lung cancer is always fatal — Modern therapies and earlier detection have substantially improved outcomes for many patients.
• Symptoms always develop early — Many lung cancers are advanced at presentation with subtle or no early symptoms.
• All lung cancers are the same — Lung cancers vary substantially in type, molecular features, and treatment implications.
• Smoking cessation doesn't help after diagnosis — Smoking cessation improves outcomes even after lung cancer diagnosis.
• Screening is only for heavy smokers — While the strongest evidence is for current and former heavy smokers, screening considerations may apply more broadly.
• Lung cancer treatment hasn't advanced — Treatment has advanced substantially with targeted therapies, immunotherapy, and various others.

⸻

Special Patient Populations

Several specific populations have particular considerations.

Non-smokers with lung cancer are more likely to have specific molecular alterations (EGFR, ALK, ROS1, and various others) responsive to targeted therapies. Younger adults with lung cancer face specific considerations including life-stage implications and often distinct molecular features. Older adults face considerations regarding comorbidities and treatment tolerance. Patients with underlying lung disease face specific challenges regarding treatment tolerance. Patients with family history may face elevated risk.

⸻

When to See a Specialist

Various specialists are involved in lung cancer care. Primary care physicians often initiate evaluation. Pulmonologists provide initial evaluation and bronchoscopy. Thoracic surgeons perform surgical resection. Medical oncologists manage chemotherapy, targeted therapy, and immunotherapy. Radiation oncologists manage radiation therapy. Pathologists provide tissue diagnosis. For complex situations, evaluation at major cancer centers provides specialized expertise.

⸻

Conclusion

Lung cancer remains one of the most challenging cancers globally, with substantial morbidity and mortality. However, advances in screening, molecular characterization, targeted therapies, immunotherapy, and various other areas have produced meaningful improvements in outcomes.

Lung cancer arises from cells in the lung tissue, with two major categories: NSCLC (85 percent) and SCLC (15 percent). NSCLC includes adenocarcinoma (most common, more in non-smokers), squamous cell carcinoma, large cell carcinoma, and various other subtypes. SCLC has aggressive growth, strong smoking association, and early metastasis tendency.

Risk factors include smoking (80 to 90 percent of cases), secondhand smoke, radon (second leading cause), occupational exposures, environmental pollution, family history, personal history of lung disease, HIV infection, and various others.

Symptoms can be subtle and often develop late. Screening with low-dose CT in high-risk individuals reduces mortality through earlier detection. Diagnosis involves imaging, biopsy, pathologic evaluation, molecular testing (EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, NTRK, PD-L1, TMB), and staging workup. NSCLC treatment varies by stage, with targeted therapies for actionable molecular alterations and immunotherapy for selected patients. SCLC treatment involves combination chemotherapy with radiation for limited stage and chemotherapy plus immunotherapy for extensive stage.

Smoking cessation matters at all stages. The combination of awareness, screening, and modern treatment provides the foundation for the best possible outcomes for this important disease.

⸻

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice. Individuals should consult a qualified healthcare provider for diagnosis and treatment.